CRISPR Therapeutics AG (CRSP) stock is soaring 5.05% in Thursday's intraday trading session, following news that Cathie Wood's Ark Invest has added to its position in the gene-editing company. The move by the influential investor appears to have sparked renewed interest in the biotech firm, despite its recent challenges.

Ark Invest, known for its focus on disruptive innovation, has been increasing its stake in CRISPR Therapeutics across several of its ETFs. This vote of confidence comes at a time when the stock has been trading significantly below its all-time highs, having lost nearly 85% of its value since early 2021. Wood's investment strategy often attracts attention from retail investors and can lead to short-term price movements.

CRISPR Therapeutics, a leader in gene-editing technology, is currently developing treatments for various diseases, including oncology, autoimmune disorders, diabetes, and cardiovascular conditions. While the company is not yet profitable and analysts don't expect it to turn a profit for several years, its potential in the rapidly evolving field of genetic medicine continues to attract interest from forward-looking investors like Ark Invest. The stock's surge today suggests that market participants are reevaluating the long-term prospects of CRISPR's innovative approach to treating genetic disorders.